[Skip to Content]
[Skip to Content Landing]
Views 7,751
Citations 0
News From the Food and Drug Administration
November 6, 2018

Preventive Migraine Drug Approved

JAMA. 2018;320(17):1746. doi:10.1001/jama.2018.16485

The FDA has approved a humanized monoclonal antibody to prevent chronic migraine headaches in adults.

Marketed as Ajovy, fremanezumab-vfrm binds to calcitonin gene-related peptide ligand and blocks it from binding to its receptor. The drug is administered by injection, either monthly or quarterly. Its ability to prevent migraine headaches was evaluated in 2 phase 3 clinical trials. In both trials, patients could use acute headache remedies and a subset in each study was allowed to use another preventive medication.